2318 GMT - A more than 20% fall in the share price of Imricor Medical Systems since it entered the ASX 300 index in early September creates a great buying opportunity for investors, according to its bull at Morgans. Imricor ended Wednesday at A$1.585, having traded as high as A$2.07 in August. Morgans suggests seasonal weakness and rising interest rates may have contributed to the share-price fall. Recent news flow has been positive. "As we move into a seasonally stronger part of the year, together with our view that material news flow (NorthStar orders, submit clinical data, FDA approval) is expected, we believe the share price should move back over A$2.00," Morgans' analyst Scott Power says. Morgans has a speculative buy call on Imricor.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.